Overview

• US scientific instruments maker's Q1 revenue rose 2.7% yr/yr, beating analyst expectations

• Adjusted EPS for Q1 was $0.31, beating analyst expectations

• Company reconfirmed FY26 revenue and adjusted EPS guidance, expects organic growth to return in Q2

Outlook

• Bruker sees FY2026 revenues of $3.57 to $3.60 bln, up 4% to 5% yoy

• Company expects FY2026 non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy

• Bruker expects a return to organic revenue growth in Q2

Result Drivers

• US ACADEMIC DEMAND WEAKNESS - Co said US academic demand continued to pressure Q1 results

• TARIFF AND CURRENCY HEADWINDS - Tariff and currency impacts weighed on Q1 performance, per CEO Frank H. Laukien

• STRONG BOOKINGS OUTSIDE US & AI DEMAND - Co saw solid academic orders for post-genomic research solutions outside the US and strong AI-driven demand in semiconductor metrology and laboratory software

Company press release: ID:nBw6rCtRfa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Bruker Corp is $45.00, about 18.4% above its May 5 closing price of $38.01

• The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.